Comind was founded by James Dacombe in 2018.

Who are Comind's investors?

Comind's investors include Angelini Ventures, Backed, Crane Venture Partners, LocalGlobe, Octopus Ventures, Phoenix Court.

Comind

Founded 2018 · 87 employees on LinkedIn · 6 known investors

Find your way into Comind

Each arrow is one introduction. Sign up to fill in the first one.

373 people can intro you to Rob

Ask Krishna Visvanathan to introduce you to Rob Cooper

You →Krishna · together at Comind →Rob

332 people can intro you to James

Ask Jamie Chen to introduce you to James Dacombe

You →Jamie · together at OLIX →James

213 people can intro you to Marc

Ask Sam Okafor to introduce you to Marc Bloom

You →Sam · together at American College of Healthcare Executives →Marc

Chema Garcia-Soto207 people can intro you

Your email: who you already know at Comind, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Comind team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

CoMind develops neuromonitoring devices and neural interfaces aimed at measuring and treating the brain to improve patient outcomes across the care continuum. It operates in the medical device and neurotechnology space serving clinical and healthcare settings.

Deep Tech Hardware Healthtech Medical Devices

Founders & leadership

Comind was founded in 2018 by James Dacombe.

James Dacombe Founder, CEOFounder at Olix

Simon MorlingChief Technology Officer

Rob Cooper Chief Scientific OfficerRob Cooper is a medical physicist with expertise in biomedical optics and optical imaging for the brain. He serves as Chief Scientific Officer at CoMind, leads the DOT-HUB research group at UCL, and co-directs NeoLAB at the Rosie Hospital in Cambridge.

Chema Garcia-Soto Chief Commercial OfficerChema Garcia-Soto spent a decade at Medtronic in medical technology roles, where he led the acquisition of Cardiored and supported post-acquisition integrations including Covidien and Touch Surgery, building relationships across global client, distributor, and investor networks. He joined CoMind as Chief Commercial Officer to apply his medtech experience to the company's neuromonitoring and neural interface platform.

Marc Bloom Chief Medical OfficerHe brings expertise in neuroanaesthesiology, neurophysiology, and biological signal analysis.

Investors · 6

Angelini Ventureslisted by Angelini VenturesRome

How we know: Angelini Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Backedlisted by BackedLondon · $500K – $5M

How we know: Backed's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Crane Venture Partnerslisted by Crane Venture PartnersLondon · $750K – $3M

How we know: Crane Venture Partners's portfolio page · the VCSheet dataset · Not right? Tell us

LocalGlobelisted by LocalGlobeLondon

How we know: phoenixcourt.vc · Not right? Tell us

Octopus Ventureslisted by Octopus VenturesLondon · $130K – $1.3M

How we know: the VCSheet dataset · Not right? Tell us

Phoenix Courtlisted by Phoenix CourtLondon

How we know: Phoenix Court's portfolio page · Not right? Tell us

Founder mafia

3 people who came through Comind went on to found or lead other companies.

Krishna VisvanathanSeed Investor & Board ObserverFounded Crane Samuel JellardResearch And Development EngineerFounded Niostem James DacombeFounder and Chief Executive OfficerFounded OLIX

Frequently asked questions

What does Comind do?: CoMind develops neuromonitoring devices and neural interfaces aimed at measuring and treating the brain to improve patient outcomes across the care continuum. It operates in the medical device and neurotechnology space serving clinical and healthcare settings.
Who founded Comind?: Comind was founded by James Dacombe in 2018.
Who are Comind's investors?: Comind's investors include Angelini Ventures, Backed, Crane Venture Partners, LocalGlobe, Octopus Ventures, Phoenix Court.